Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside ChinaCompanies: GSKHUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces that further to its announcement on September 3, 2026 and following the completion of customary closing conditions including antitrust regulatory reviews, the exclusive development and license agreement between HUTCHMED Limited (a subsidiary of the Company) and a subsidiary of GSK plc (“GSK”) has closed. The agreement grants the GSK subsidiary worldwide rights excluding Mainland China, Hong Kong, Macau and Taiwan to develop and commercialize HMPL-A830.